FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3033866734> ?p ?o ?g. }

• W3033866734 endingPage "568" @default.
• W3033866734 startingPage "560" @default.
• W3033866734 abstract "Background: Induction of antibiotic resistance is associated with increased morbidity and mortality in AmpC β-lactamase producing Enterobacteriaceae. The use of ceftriaxone is controversial for treatment of these organisms due to concerns for inducible resistance. This study was designed to compare treatment failure rates between ceftriaxone and antipseudomonal β-lactam antibiotics when used as definitive therapy for organisms most commonly associated with chromosomal AmpC β-lactamase production. Methods: A retrospective, single-center cohort study was performed enrolling patients hospitalized with monomicrobial Enterobacter, Citrobacter, or Serratia spp. infections. The primary objective compared proportion of treatment failure between groups. All patients received either ceftriaxone or an antipseudomonal β-lactam alone within 24 hours of culture finalization, and with a duration of at least 72 hours for definitive treatment. Treatment failure was defined as either clinical failure (abnormal white blood cell count or temperature on day 7 or 14 post-antibiotics) or microbiologic failure (regrowth of the same organism at same site within 14 or 21 days). Results: Of 192 total patients, treatment failure was observed in 24/71 patients (34%) receiving ceftriaxone and in 42/121 patients (35%) receiving antipseudomonal β-lactam ( P = .98). No difference was observed between clinical or microbiologic failure rates between groups. The ceftriaxone group had significantly more patients undergoing treatment for urinary tract infections (51% vs 17%, P < .001), but treatment failure rates remained similar between groups when comparing infections of all other sources. Conclusion: Ceftriaxone has comparable treatment failure rates to antipseudomonal β-lactams for susceptible Enterobacteriaceae infections and may be considered as a therapeutic option. Further, prospective research is needed to validate optimal dosing and application in all sites of infection." @default.
• W3033866734 created "2020-06-12" @default.
• W3033866734 creator A5020982310 @default.
• W3033866734 creator A5034106131 @default.
• W3033866734 creator A5036992065 @default.
• W3033866734 creator A5064484538 @default.
• W3033866734 creator A5081153925 @default.
• W3033866734 date "2020-06-04" @default.
• W3033866734 modified "2023-09-26" @default.
• W3033866734 title "Comparison of Ceftriaxone and Antipseudomonal β-Lactam Antibiotics Utilized for Potential AmpC β-Lactamase-Producing Organisms" @default.
• W3033866734 cites W129634086 @default.
• W3033866734 cites W1572362092 @default.
• W3033866734 cites W1744685958 @default.
• W3033866734 cites W1898928487 @default.
• W3033866734 cites W1912467192 @default.
• W3033866734 cites W1967624732 @default.
• W3033866734 cites W2020459071 @default.
• W3033866734 cites W2036219845 @default.
• W3033866734 cites W2041215841 @default.
• W3033866734 cites W2047471128 @default.
• W3033866734 cites W2082321986 @default.
• W3033866734 cites W2099303284 @default.
• W3033866734 cites W2100067485 @default.
• W3033866734 cites W2101382361 @default.
• W3033866734 cites W2108638835 @default.
• W3033866734 cites W2125863771 @default.
• W3033866734 cites W2129717936 @default.
• W3033866734 cites W2132341797 @default.
• W3033866734 cites W2143874510 @default.
• W3033866734 cites W2147778708 @default.
• W3033866734 cites W2152127318 @default.
• W3033866734 cites W2165158988 @default.
• W3033866734 cites W2167275970 @default.
• W3033866734 cites W2594164101 @default.
• W3033866734 cites W2600757231 @default.
• W3033866734 cites W2768146862 @default.
• W3033866734 cites W2786886659 @default.
• W3033866734 cites W2884524290 @default.
• W3033866734 cites W2892368225 @default.
• W3033866734 cites W2902532896 @default.
• W3033866734 cites W2916638675 @default.
• W3033866734 cites W2921330592 @default.
• W3033866734 doi "https://doi.org/10.1177/0018578720931463" @default.
• W3033866734 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8554594" @default.
• W3033866734 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34720161" @default.
• W3033866734 hasPublicationYear "2020" @default.
• W3033866734 type Work @default.
• W3033866734 sameAs 3033866734 @default.
• W3033866734 citedByCount "3" @default.
• W3033866734 countsByYear W30338667342021 @default.
• W3033866734 countsByYear W30338667342022 @default.
• W3033866734 countsByYear W30338667342023 @default.
• W3033866734 crossrefType "journal-article" @default.
• W3033866734 hasAuthorship W3033866734A5020982310 @default.
• W3033866734 hasAuthorship W3033866734A5034106131 @default.
• W3033866734 hasAuthorship W3033866734A5036992065 @default.
• W3033866734 hasAuthorship W3033866734A5064484538 @default.
• W3033866734 hasAuthorship W3033866734A5081153925 @default.
• W3033866734 hasBestOaLocation W30338667342 @default.
• W3033866734 hasConcept C104317684 @default.
• W3033866734 hasConcept C126322002 @default.
• W3033866734 hasConcept C185592680 @default.
• W3033866734 hasConcept C2776450100 @default.
• W3033866734 hasConcept C2776520383 @default.
• W3033866734 hasConcept C2778983983 @default.
• W3033866734 hasConcept C2781463711 @default.
• W3033866734 hasConcept C501593827 @default.
• W3033866734 hasConcept C523546767 @default.
• W3033866734 hasConcept C54355233 @default.
• W3033866734 hasConcept C547475151 @default.
• W3033866734 hasConcept C55493867 @default.
• W3033866734 hasConcept C64778159 @default.
• W3033866734 hasConcept C71924100 @default.
• W3033866734 hasConcept C86803240 @default.
• W3033866734 hasConcept C89423630 @default.
• W3033866734 hasConceptScore W3033866734C104317684 @default.
• W3033866734 hasConceptScore W3033866734C126322002 @default.
• W3033866734 hasConceptScore W3033866734C185592680 @default.
• W3033866734 hasConceptScore W3033866734C2776450100 @default.
• W3033866734 hasConceptScore W3033866734C2776520383 @default.
• W3033866734 hasConceptScore W3033866734C2778983983 @default.
• W3033866734 hasConceptScore W3033866734C2781463711 @default.
• W3033866734 hasConceptScore W3033866734C501593827 @default.
• W3033866734 hasConceptScore W3033866734C523546767 @default.
• W3033866734 hasConceptScore W3033866734C54355233 @default.
• W3033866734 hasConceptScore W3033866734C547475151 @default.
• W3033866734 hasConceptScore W3033866734C55493867 @default.
• W3033866734 hasConceptScore W3033866734C64778159 @default.
• W3033866734 hasConceptScore W3033866734C71924100 @default.
• W3033866734 hasConceptScore W3033866734C86803240 @default.
• W3033866734 hasConceptScore W3033866734C89423630 @default.
• W3033866734 hasIssue "5" @default.
• W3033866734 hasLocation W30338667341 @default.
• W3033866734 hasLocation W30338667342 @default.
• W3033866734 hasLocation W30338667343 @default.
• W3033866734 hasOpenAccess W3033866734 @default.
• W3033866734 hasPrimaryLocation W30338667341 @default.
• W3033866734 hasRelatedWork W1891571052 @default.

• next